Strategic Call for Support – Advancing Neurodivergent Inclusion and Access to ADHD Treatment in France & Europe

 

 

To the Executive Leadership of Takeda, Teva, Janssen, Novartis, Eli Lilly, Neuraxpharm, and Allied Manufacturers

 

I write to you today not merely as the founder of TDAH France – Comprendre & Agir, but as a voice for the millions of individuals in France and across Europe who continue to suffer in silence due to underdiagnosed and undertreated Dopaminergic Deficit Disorder (DDD), commonly referred to as ADHD.

 

On August 12, 2025, our association reached a historic milestone: the official submission of a national dossier to the Haute Autorité de Santé, calling for the recognition of DDD as a distinct and urgent public health concern. This initiative is not a campaign—it is a movement. One that seeks to dismantle stigma, correct decades of clinical misdirection, and restore dignity to those whose neurodivergence has been pathologized or ignored.

 

We have taken the bumpier road, and we are fighting all alone. Your support—combined with a collective interest—could make the difference and benefit all parties involved, including patients, clinicians, researchers, and the pharmaceutical industry itself.

 🔍 What We Are Asking

 

 

We respectfully invite your organization to consider the following forms of strategic support:

 

- Public endorsement of our national initiative and dossier 

- Participation in roundtable discussions with clinicians, patient advocates, and policymakers 

- Support for educational campaigns on ADHD and DDD, targeting both professionals and the public 

- Collaboration on access programs to ensure equitable availability of stimulant-based treatments 

- Scientific engagement to advance research on dopaminergic dysfunction and neurodivergent profiles

 

 🌍 Why It Matters

 

France lags behind its OECD peers in ADHD recognition, diagnosis, and treatment. The consequences are measurable: academic failure, professional exclusion, emotional distress, and—tragically—avoidable suicide. Our unofficial estimate suggests that up to 60% of suicides among young adults in Switzerland may be linked to untreated DDD. We cannot afford to wait for similar data in France to act.

 

Your organization has already demonstrated leadership in developing and distributing life-changing treatments. We believe that your voice, your expertise, and your commitment to ethical innovation can help catalyze a new era of neurodivergent inclusion.

 

 

 🤝 Let’s Build It Together

 

We are not asking for charity. We are inviting partnership. A shared investment in a future where ADHD is not a label of limitation, but a gateway to understanding, creativity, and resilience.

 

Please contact us directly to arrange a meeting or request further documentation:

 

Paul Cambria 

Founder, TDAH France – Comprendre & Agir 

📧 contact@tdahfrance.onmicrosoft.com

🌐 https://www.tdahfrance.com

📍 Vichy, France | SIREN: 945 320 109 | RNA: W033007988